Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hester BiosciencesBOM:524669 +0.37%72 Days Payable is 115.79 as of Mar. 2026, which is 16% above its 10-year median of 100.18. GuruFocus rates BOM:524669 with a GF Score™ of 72/100 and a GF Value™ of ₹1,891.98 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 927 Drug Manufacturers companies, Hester Biosciences ranks better than 66.67% on this metric.
The historical rank and industry rank for Hester Biosciences's Days Payable or its related term are showing as below:
BOM:524669'
s Days Payable Range Over the Past 10 Years
Min: 55.11 Med: 100.18 Max: 148.87
Current: 122.67
During the past 13 years, Hester Biosciences's highest Days Payable was 148.87. The lowest was 55.11. And the median was 100.18.
BOM:524669's Days Payable is ranked better than 66.67% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:524669: 122.67
Hester Biosciences's Days Payable
declined
from Mar. 2025 (129.42) to Mar. 2026 (115.79).
It may suggest that Hester Biosciencesaccelerated paying its suppliers.
Hester Biosciences Days Payable Related Terms
Hester Biosciences Days Payable Historical Data
* Premium members only.
The historical data trend for Hester Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hester Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hester Biosciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hester Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Hester Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Hester Biosciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hester Biosciences (BOM:524669) has a Days Payable of 115.79 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hester Biosciences and its competitors. This is 16% above median its historical median of 100.18. Over the past decade, Hester Biosciences' Days Payable has ranged from 55.11 to 148.87. According to the industry distribution chart, Hester Biosciences ranks #309 out of 927 companies in the Drug Manufacturers industry, placing it in the top 33.3%.
Is Hester Biosciences' Days Payable too high?
Hester Biosciences' current Days Payable of 115.79 is 16% above median its 10-year median of 100.18. Over the past 10 years, this metric has ranged from a low of 55.11 to a high of 148.87. The Drug Manufacturers industry median Days Payable is 90.38. Hester Biosciences' value of 115.79 is 28.1% above this industry median. Based on the distribution chart, Hester Biosciences ranks #309 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hester Biosciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hester Biosciences' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hester Biosciences ranks #309 out of 927 companies for Days Payable. This puts Hester Biosciences in the upper half of its industry. The industry median Days Payable is 90.38. Hester Biosciences' value of 115.79 is 28.1% above this benchmark. Historically, Hester Biosciences' own Days Payable has ranged from 55.11 to 148.87 over the past decade. While the company's 10-year median is 100.18 vs. the industry median of 90.38, Hester Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hester Biosciences's current Days Payable of 115.79 is 28.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hester Biosciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hester Biosciences's current Days Payable is 115.79, which is 16% above median its own 10-year median of 100.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hester Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Hester Biosciences (BOM:524669) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,891.98, compared to a current price of ₹2,445.15 — trading 29.2% above its estimated fair value. The current Days Payable is 115.79, which is 16% above median its 10-year median of 100.18 and 28.1% above the Drug Manufacturers industry median of 90.38. Hester Biosciences' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hester Biosciences (BOM:524669), the current Days Payable is 115.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hester Biosciences (BOM:524669) Overvalued in 2026?
Based on GuruFocus' analysis, Hester Biosciences stock appears to be overvalued.
The current stock price of ₹2,445.15 is trading 29.2% above its estimated GF Value™ of ₹1,891.98.
GuruFocus considers Hester Biosciences to be Modestly Overvalued.
Key valuation signals for BOM:524669:
Days Payable: 115.79 (16% above median its 10-year median of 100.18)
GF Value™: ₹1,891.98 vs. price of ₹2,445.15 (29.2% above fair value)
Industry Position: 28.1% above the Drug Manufacturers median (#309 of 927)
No single metric tells the full story. See the BOM:524669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hester Biosciences Ltd is an India-based animal healthcare company. It is principally engaged in the manufacturing of veterinary vaccines and trading of veterinary health products such as goat pox vaccine, PPR vaccines, etc. The group has two principal operating and reporting segments, viz. Poultry healthcare and Animal healthcare. Maximum revenue is generated from the Poultry Healthcare segment, which offers various solutions encompassing vaccines, health products, and feed supplements, supported and packaged by its diagnostic services, R&D, quality standards, and field support, to help farmers protect flock health, enhance productivity, and drive long-term farm sustainability. Geographically, it generates maximum revenue within India, and also exports its products to other markets.
72GF Score
Get the complete analysis for BOM:524669
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524669 has been successfully added to your 
